Daptomycin
Also known as: Cubicin, Cubicin RF, Daptomycin, Daptomycin for injection, LY146032
Source Daptomycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Daptomycin is a cyclic lipopeptide antibiotic administered intravenously for serious Gram‑positive infections. It is approved for use in conditions such as methicillin‑resistant Staphylococcus aureus (MRSA) bacteremia, vancomycin‑resistant Enterococcus (VRE) bloodstream infections, and other difficult‑to‑treat Gram‑positive infections.
Mechanism of Action
Daptomycin inserts into the bacterial cell membrane in a calcium‑dependent manner, forming complexes that cause rapid depolarisation and loss of membrane potential. This disruption halts protein, DNA and RNA synthesis, leading to bacterial cell death. Reported resistance mechanisms include alterations that reduce drug binding or ‘trapping’ of the molecule within the membrane.
What the Research Shows
A 2024 meta‑analysis of Enterococcus faecalis isolates identified daptomycin as one of the few agents with low resistance prevalence, suggesting effectiveness against this pathogen. Clinical reviews of Staphylococcus aureus bacteremia note that daptomycin is a standard empiric option for MRSA and has demonstrated non‑inferior outcomes compared with vancomycin in phase‑3 trials. A head‑to‑head study of ceftobiprole versus daptomycin showed comparable overall treatment success and mortality rates. Systematic reviews of MRSA bacteremia report similar efficacy and safety of daptomycin relative to linezolid and vancomycin. Reviews of VRE bloodstream infections highlight daptomycin as a key therapeutic, with therapeutic drug monitoring recommended to optimise dosing.
Reported Benefits
Evidence indicates daptomycin retains activity against MRSA, VRE, and drug‑resistant Enterococcus faecalis, with low reported resistance rates in recent surveys. Clinical trials have shown it to be non‑inferior to vancomycin and to newer agents such as ceftobiprole for complicated bacteremia, offering an alternative when other drugs fail or are contraindicated.
Limitations of the Evidence
Resistance to daptomycin has emerged in some Staphylococcus aureus strains via membrane‑altering mutations, and the exact mechanisms remain incompletely understood. Optimal dosing strategies, especially for VRE infections, require therapeutic drug monitoring, and data on long‑term outcomes beyond bacteremia are limited. Most published evidence focuses on bloodstream infections rather than other infection sites.
Safety Considerations
Adverse events were reported in roughly 60 % of patients receiving daptomycin in clinical trials, with serious adverse events occurring in about 20 % of cases. Specific safety concerns include muscle toxicity (elevated creatine kinase) and rare eosinophilic pneumonia, necessitating clinical monitoring during therapy. Renal function and inflammatory markers should be assessed regularly.
How It Is Administered
Daptomycin is supplied for intravenous infusion only. In clinical studies, dosing ranged from 6 mg/kg to 10 mg/kg administered once daily. The formulation is a sterile solution for injection, requiring reconstitution and infusion over a specified period as directed by prescribing information.
Routes of Administration
Goals & Uses
- MRSA osteomyelitisInfectious DiseaseModerate
- Complicated skin and skin structure infections (cSSSI)AntibacterialHigh
- Treatment of MRSA infectionsAntimicrobialHigh
- Left-sided endocarditis (gram-positive)Infectious DiseaseModerate
- Staphylococcus aureus bacteremiaInfectious DiseaseHigh
- Vancomycin-resistant Enterococcus (VRE) infectionsInfectious DiseaseModerate
Contraindications
- Hypersensitivity to daptomycinAllergyHigh
- PneumoniaDisease SpecificHigh
- Concurrent high‑dose statin therapyDrug InteractionModerate
- Known hypersensitivity to daptomycinAllergyHigh
Adverse Effects
- Peripheral neuropathyNeurologicalUncommon
- Gastrointestinal upsetGastrointestinalCommon
- Skeletal muscle toxicity (myopathy/rhabdomyolysis)MusculoskeletalUncommon
- Gastrointestinal disturbancesGastrointestinalCommon
- Eosinophilic pneumoniaPulmonaryUncommon
- Myopathy / elevated CPKMusculoskeletalCommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Infusion site reactionsLocalCommon
Drug Interactions
- TobramycinLow
- Statins (e.g., simvastatin, lovastatin)Moderate
- HMG-CoA reductase inhibitors (statins)Moderate
- WarfarinModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patients (<1 year)AgeAbsolute
- Renal impairment (CrCl <30 mL/min)RenalRelative
- Severe renal impairment (CrCl <30 mL/min)Organ ImpairmentRelative
- Pre-existing myopathy or elevated CKMusculoskeletalRelative
Regulatory Status
- European UnionApprovedApproved: Complicated skin and soft‑tissue infections, S. aureus bacteremia, Right‑sided endocarditisSame indications as US; marketed as Cubicin
- United StatesApprovedApproved: Complicated skin and soft‑tissue infections, S. aureus bacteremia, Right‑sided endocarditisPrescribed as intravenous infusion; dosing adjusted for renal function
- United KingdomApprovedApproved: Complicated skin and soft tissue infections, Staphylococcus aureus bacteremia and right-sided endocarditisApproved via MHRA; retained EU approval post-Brexit
FDA‑approved in 2003 (Cubicin) for S. aureus bacteremia, right‑sided endocarditis, and cSSSI; EMA approval for similar indications.
Evidence & Sources
- Journal ArticleHighGuan L, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModeratePantosti A, Sanchini A, Monaco M2007-01-01T00:00:00.000000Z
- Journal ArticleModerateTong SYC, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateHolland TL, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateCairns KA, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateKawasuji H, et al.2023-01-01T00:00:00.000000Z
Frequently Asked Questions
What infections is daptomycin approved to treat?
It is approved for serious Gram‑positive infections, notably MRSA bacteremia, right‑sided endocarditis, and bloodstream infections caused by vancomycin‑resistant Enterococcus.
How does daptomycin differ from vancomycin?
Daptomycin acts by disrupting the bacterial cell membrane, whereas vancomycin inhibits cell‑wall synthesis. Clinical trials show daptomycin provides comparable cure rates in bacteremia, with a different side‑effect profile.
Is resistance to daptomycin common?
Current surveillance indicates low resistance rates in Enterococcus faecalis, but emerging resistance has been reported in Staphylococcus aureus through membrane‑altering mutations, highlighting the need for susceptibility testing.
What monitoring is needed during daptomycin therapy?
Patients should have regular checks of creatine kinase levels to detect muscle toxicity, and clinical assessment for signs of eosinophilic pneumonia. Therapeutic drug monitoring may be used for VRE infections to optimise dosing.
Can daptomycin be used for infections outside the bloodstream?
Evidence primarily supports its use in bloodstream infections; data for other sites, such as pneumonia, are limited because daptomycin is inactivated by pulmonary surfactant.
What is Daptomycin?
Daptomycin is a cyclic lipopeptide antibiotic administered intravenously for serious Gram‑positive infections. It is approved for use in conditions such as methicillin‑resistant Staphylococcus aureus (MRSA) bacteremia, vancomycin‑resistant Enterococcus (VRE) bloodstream infections, and other difficult‑to‑treat Gram‑positive infections.
What is Daptomycin used for?
Daptomycin is educationally associated with: MRSA osteomyelitis, Complicated skin and skin structure infections (cSSSI), Treatment of MRSA infections, Left-sided endocarditis (gram-positive), Staphylococcus aureus bacteremia, Vancomycin-resistant Enterococcus (VRE) infections. Educational only — not medical advice.
How is Daptomycin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Daptomycin?
Reported adverse effects include: Peripheral neuropathy, Gastrointestinal upset, Skeletal muscle toxicity (myopathy/rhabdomyolysis), Gastrointestinal disturbances, Eosinophilic pneumonia, Myopathy / elevated CPK, Elevated liver enzymes, Infusion site reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Daptomycin?
Recorded contraindications: Hypersensitivity to daptomycin, Pneumonia, Concurrent high‑dose statin therapy, Known hypersensitivity to daptomycin. Consult a qualified clinician before use.